Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor

Kwonoh Park; Jae-Lyun Lee; Jin-Hee Ahn; Kyoo Hyung Lee; In-Gab Jeong; Cheryn Song; Bumsik Hong; Jun Hyuk Hong; Hanjong Ahn
October 2014
Cancer Research & Treatment;2014, Vol. 46 Issue 4, p339
Academic Journal
Purpose The purpose of this study is to assess the efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma (mRCC) for whom initial treatment with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) has failed. Materials and Methods Eligible patients with mRCC (any histology) who had progressed on or were intolerant of VEGFr-TKI therapy received oral everolimus (10 mg dose once daily). Tumor response was reassessed according to Response Evaluation Criteria in Solid Tumors (RECIST). Results This study included 100 patients with a median follow-up duration of 10.2 months, a median progression-free survival (PFS) of 4.2 months (95% confidence interval [CI], 3.4 to 5.0 months), and an overall survival of 10.1 months (95% CI, 6.9 to 13.3 months). The most common grade 3 or greater adverse events (AEs) overall were anemia (13%), pneumonitis (9%), hyperglycemia (8%), and stomatitis (6%). While the incidence of pneumonitis was similar (26 cases, 26%) to the reported incidence in Western patients, the Korean presentations were more severe: 10 patients permanently discontinued everolimus due to pneumonitis, including two deaths on treatment. Statistically significant relationships were established between biologic toxicities, hyperglycemia and anemia, and PFS (hyperglycemia vs. non-hyperglycemia: hazard ratio [HR], 0.61; p=0.055 and anemia vs. non-anemia: HR, 0.51; p=0.021). Conclusion Everolimus was effective in Korean patients with mRCC who had failed initial VEGFr-TKI therapy. While everolimus was well tolerated in general and the AE incidence of this study was similar to those of previous reports, severe pneumonitis was common. Hyperglycemia and anemia showed significant correlation with PFS and thus may be potentially useful as prognostic indicators.


Related Articles

  • Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives. Narayan, Vivek; Haas, Naomi Balzer // International Journal of Nephrology & Renovascular Disease;Mar2016, Vol. 9, p65 

    Background: Axitinib is a next-generation, selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors. It is approved for the treatment of metastatic renal cell carcinoma (mRCC) based on a demonstrated progression-free survival advantage over sorafenib in the...

  • Vitiligo: A new side effect of everolimus therapy for metastatic renal cell carcinoma. Cacciapuoti, Sara; Masarà, Anna; Mariano, Maria; Cameli, Norma; Fabbrocini, Gabriella // Australasian Medical Journal;2017, Vol. 10 Issue 10, p898 

    Patients with metastatic renal cell carcinoma (mRCC) have always had a poor prognosis. Recently new targeted drugs were developed. A 73-year-old female patient affected from mRCC was assessed at our Department. She underwent before a multitargeted tyrosine kinase inhibitor (TKI) therapy, but she...

  • Sorafenib in Renal Cell Carcinoma: Decision Algorithm. Vázquez, Sergio; León, Luis; Lázaro, Martín // Cancer & Chemotherapy Reviews;Apr-Jun2014, Vol. 9 Issue 2, p61 

    Molecular-targeted therapy with multikinase inhibitors has been recommended as first-choice therapy in advanced renal cell carcinoma. Sorafenib is a tyrosine kinase inhibitor able to inhibit vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and Raf kinase,...

  • Possible Prognostic and Therapeutic Significance of c-Kit Expression, Mast Cell Count and Microvessel Density in Renal Cell Carcinoma. Marech, Ilaria; Gadaleta, Cosmo Damiano; Ranieri, Girolamo // International Journal of Molecular Sciences;Jul2014, Vol. 15 Issue 7, p13060 

    Renal cell carcinoma (RCC) is the most frequent renal tumor and its incidence is increasing worldwide. Tumor angiogenesis is known to play a crucial role in the etiopathogenesis of RCC and over the last few years an even deeper knowledge of its contribution in metastatic RCC development has led...

  • Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor. Park, Inkeun; Lee, Jae-Lyun; Ahn, Jin-Hee; Lee, Dae-Ho; Lee, Kyoo-Hyung; You, Dalsan; Jeong, In; Song, Cheryn; Hong, Bumsik; Hong, Jun; Ahn, Hanjong // Cancer Chemotherapy & Pharmacology;May2015, Vol. 75 Issue 5, p1025 

    Purpose: To assess the efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for metastatic renal cell carcinoma (mRCC) patients and to identify predictive factors for increased progression-free survival (PFS) or overall survival (OS). Methods:...

  • Effect of axitinib on the QT interval in healthy volunteers. Ruiz-Garcia, Ana; Houk, Brett; Pithavala, Yazdi; Toh, Melvin; Sarapa, Nenad; Tortorici, Michael // Cancer Chemotherapy & Pharmacology;Mar2015, Vol. 75 Issue 3, p619 

    Purpose: Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1-3, approved for second-line treatment of advanced renal cell carcinoma (RCC). Preclinical studies did not indicate potential for axitinib-induced delayed cardiac repolarization. Methods: The...

  • Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib. Richter, Suzanne; Jo-An Seah; Pond, Gregory R.; Gan, Hui K.; Mackenzie, Mary J.; Hotte, Sebastien J.; Mukherjee, Som D.; Murray, Nevin; Kollmannsberger, Christian; Heng, Daniel; Haider, Masoom A.; Halford, Robert; Ivy, S. Percy; Moore, Malcolm J.; Sridhar, Srikala S. // Canadian Urological Association Journal;nov/dec2014, Vol. 8 Issue 11/12, p398 

    Introduction: Pivotal phase III trials have positioned angiogenesis inhibitors as first-line therapy for the management of most advanced or metastatic renal cell carcinomas (mRCC). Approaches to secondline therapy, however, remain more controversial with respect to drug selection and drug...

  • A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Strosberg, J. R.; Weber, J. M.; Choi, J.; Campos, T. L.; Valone, T. L.; Han, G.; Schell, M. J.; Kvols, L. K. // Annals of Oncology;Sep2012, Vol. 23 Issue 9, p2335 

    Background The liver is the predominant site of metastases among patients with advanced neuroendocrine tumors (NETs). Prior retrospective studies have reported high response rates in patients treated with transarterial embolization (TAE). NETs are highly vascular and are known to express...

  • Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma. Gunnarsson, Orvar; Pfanzelter, Nicklas R.; Cohen, Roger B.; Keefe, Stephen M. // Cancer Management & Research;2015, Vol. 7, p65 

    Axitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor-α, and c-kit. Phase I studies demonstrated 5 mg twice daily as the recommended starting dose with notable effects seen in renal cell carcinoma, an observation...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics